Annals of Surgical Oncology

The Inner Circle Acknowledges, Hank C. Hill as a Pinnacle Life Member

Retrieved on: 
Monday, January 29, 2024
Surgical oncology, Philosophy, Neoplasm, Patient, Annals of Surgical Oncology, Research, Endocrine system, Sarcoma, Radiation, ABS, General surgery, Mentorship, Dance, Health, Multimedia, Knowledge, Music, Inner circle, Surgeon, National Research Service Award, Society, University, MD Anderson Cancer Center, Cancer, Skin, Gastrointestinal tract, Harlem Hospital Center, Esophagus, NIH, Liver, Stomach, Rectum, T-32, Morehouse School of Medicine, Breast, Tennis, Education, Publication, Pancreas, Endoscopy, Nursing

BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.

Key Points: 
  • BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.
  • Dr. Hill pursued higher education at the Brooklyn Campus of Long Island University where he earned his Bachelor of Science degree in Biology/Pre-Med.
  • Anderson Cancer Center in Houston, where he earned a surgical oncology research fellowship certificate in tumor biology.
  • Aside from his professional pursuits, Dr. Hill enjoys traveling, dancing (soca, reggae, reggaeton, R&B), and listening to music.

Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"

Retrieved on: 
Wednesday, December 13, 2023
School, Woman, Ultimate, Cryoablation, Freezing, Study, Surgery, Breast cancer, Surgical oncology, Patient, Mammography, Breast, Neoplasm, Annals of Surgical Oncology, Quality of life, Life, ICE3, Medical imaging, Pharmaceutical industry

A total of 32 early-stage breast cancer patients with a median age of 70 (range of 50-91) were treated with cryoablation.

Key Points: 
  • A total of 32 early-stage breast cancer patients with a median age of 70 (range of 50-91) were treated with cryoablation.
  • Six of the 32 patients (18.5%) received adjuvant radiation, and 31 of 32 patients (97%) received adjuvant endocrine therapy.
  • The mean follow-up was 15 months, with 20 patients (62.5%) completing two years, and 12 patients (37.5%) completing more than three years.
  • Stated study co-author, Dr. Rakhshanda Layeequr Rahman
    "This independent study is quite compelling in that it goes beyond providing data.

New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint®

Retrieved on: 
Thursday, September 28, 2023
Blueprint, Lymphedema, Surgical oncology, Neoadjuvant therapy, NCT, Neoplasm, Cancer, Woman, Breast, Gene expression profiling, MS, MINT, TAD, Annals of Surgical Oncology, MD, Patient, Lymph, Risk, Rollcage Stage II, Health, III, Breast cancer, Medical imaging, MammaPrint

IRVINE, Calif. & AMSTERDAM, Sept. 28, 2023 /PRNewswire/ -- Agendia®, Inc., a global leader in innovative genomic technology and diagnostic tests, announced today the publication of the Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial, a prospective study designed to evaluate the utility of molecular profiling alongside traditional pathologic and clinical prognostic factors in predicting the response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (LABC).

Key Points: 
  • This is the first neoadjuvant study to show that nodal downstaging in response to neoadjuvant therapy can be predicted by MammaPrint + BluePrint, Agendia's advanced genomic assays.
  • The MINT trial represents a collaboration of leading institutions and researchers dedicated to advancing breast cancer treatment.
  • It reaffirms the commitment of the scientific and medical communities to improve patient care and outcomes through cutting-edge research.
  • For more information about Agendia, visit www.agendia.com and follow Agendia on Facebook , Twitter ,  and LinkedIn .

The Inner Circle Acknowledges, Sharona B. Ross, MD, FACS as a Life Achiever for her contributions to the field of Gastroenterology

Retrieved on: 
Wednesday, July 5, 2023
Surgical oncology, Society, Patient, Inner circle, SESC, Extrapyramidal system, LESS, Congress, Journal, ACS, Robotics, Division, Artificial intelligence, American College, News, University, Surgical Endoscopy, AHPBA, SSAT, Committee, Pancreas, Innovation, AFI Life Achievement Award, SLS, Nursing, Council, Liver, HPB, SRS, Gallbladder, IDF, Multimedia, GERD, Annals of Surgical Oncology, Journal of Gastrointestinal Surgery, Love, Justin, Cancer, Family, General surgery, Research-on-Research Committee, Surgeon, Esophagus, University of South Florida, Golf, Technical Guidelines Development Committee, Stomach, Physician, Executive Committee, FACS, Education Committee, MIS, Canning, Dentistry, MD, Woman, Gastroenterology

TAMPA, Fla., July 5, 2023 /PRNewswire/ -- Prominently featured as the upcoming cover story in The Inner Circle, Sharona B. Ross, MD, FACS is acknowledged as a Life Achiever for her contributions to the field of Gastroenterology.

Key Points: 
  • TAMPA, Fla., July 5, 2023 /PRNewswire/ -- Prominently featured as the upcoming cover story in The Inner Circle, Sharona B. Ross, MD, FACS is acknowledged as a Life Achiever for her contributions to the field of Gastroenterology.
  • and completed a General Surgery residency at the University of South Florida College of Medicine Department of General Surgery in 2006.
  • She was distinguished from her peers when awarded the prestigious HPB/Advanced Gastrointestinal Surgery and Minimally Invasive Surgery Fellowship at USF/Tampa General Hospital in 2007.
  • Highly sought after in her field, Dr. Ross participates in various committees at AdventHealth Tampa to determine the quality of care delivered.

Novian Health Earns New Product Innovation Award for Novilase Breast Therapy

Retrieved on: 
Tuesday, December 6, 2022
Laser, Perception, Annals of Surgical Oncology, Coagulative necrosis, Scar, Breast, Laser medicine, Patient, Frost, Sengupta, Breast cancer, Fatigue, Neoplasm, FDA, Health, Woman, Surgical oncology, Quality of life, Trauma, Cancer, Record, Multimedia, Temperature, Malignancy, Medical imaging, Pharmaceutical industry

CHICAGO, Dec. 6, 2022 /PRNewswire/ -- Novian Health has received Frost & Sullivan's 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase® Breast Therapy system. Novilase, a minimally invasive procedure that uses laser ablation to destroy tumors as an alternative to surgery, has the potential to make "the treatment of breast cancer much simpler and more effective, with significantly lower side effects," according to Frost & Sullivan's evaluation.

Key Points: 
  • CHICAGO, Dec. 6, 2022 /PRNewswire/ -- Novian Health has received Frost & Sullivan's 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase Breast Therapy system.
  • Novilase is a thermal ablation device that uses laser heat to destroy tumor cells without lumpectomy surgery.
  • "Laser therapy can help patients avoid the trauma and risks of breast cancer surgery," said Henry Appelbaum, president and CEO of Novian Health.
  • "The Novian Health team is proud to receive this award as we begin to offer the benefits of this game-changing technology to breast cancer patients in Europe."

Dr. Alina Sholar Continues Partnership With Exclusive Haute Beauty Network

Retrieved on: 
Wednesday, February 9, 2022
Annals, American Board of Plastic Surgery, Woman, Beauty, Republic, University of Louisville School of Medicine, Plastic surgery, Science, Howard Brody, Daughters of the Republic of Texas, General surgery, Nelda, Veterinary medicine, Infection, Student, Dermatology, Anatomy, Moses Austin, Patient, Microsurgery, University, Publication, Annals of Plastic Surgery, American Board of Commissioners for Foreign Missions, Plastic and Reconstructive Surgery, Family, College, Animal, Daughter, Cleft lip and cleft palate, Virginia–Maryland College of Veterinary Medicine, Biomedical sciences, Achievement, Perfusion, Annals of Surgical Oncology, Haute Living, Music, Surgical oncology, BS, Texas A&M University, Dentistry, Fashion, Plastic, Medicine

Leading by example, Dr. Sholar not only 'talks the talk,' but 'walks the walk' when it comes to advocating for her patients' best selves.

Key Points: 
  • Leading by example, Dr. Sholar not only 'talks the talk,' but 'walks the walk' when it comes to advocating for her patients' best selves.
  • Dr. Sholar is the first physician in her family, but she knew even in her elementary years what she may become.
  • As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.
  • For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/
    Brooke Klaiman, Haute Beauty by Haute Living, 5612122126, [email protected]

Juva Life Files Patent on Family of Non-Cannabinoid Small Molecules Targeting Consumer and Pharma Inflammatory Indications

Retrieved on: 
Thursday, October 14, 2021
Journal, American College, Literature, Surgical oncology, Surgery, CSE, Breast cancer, Executive Committee, The New England Journal of Medicine, Society, Knowledge, Therapy, Annals of Surgical Oncology, USPTO, JAMA, American Medical Association, United States Patent and Trademark Office, Chemistry, Board of directors, American Society of Breast Surgeons, American Board of Surgery, Inflammation, News, Annual general meeting, American Board of Commissioners for Foreign Missions, National academy, GLOBE, Journal of Clinical Oncology, National Academies of Sciences, Engineering, and Medicine, Patent, THE, S-1 Executive Committee, Company, Fellowship of the Royal Colleges of Surgeons, Oxidative stress, Board, Research, BOARD, Melanoma, Pharmaceutical industry, Management

JUVA-19 is a non-cannabinoid small molecule isolated from cannabis with previous unappreciated broad spectrum anti-inflammatory properties.

Key Points: 
  • JUVA-19 is a non-cannabinoid small molecule isolated from cannabis with previous unappreciated broad spectrum anti-inflammatory properties.
  • Additionally, the company has identified candidate targets consistent with the regulation of oxidative stress and inflammation.
  • Juva Life is availing itself of the significant body of literature suggestive of therapeutic benefits of cannabis coupled to modern drug discovery and deep learning tools.
  • The companys strategy is to develop natural and semi-synthetic compositions alone and in combination for the consumer anti-inflammatory marketplace, and in parallel chemically optimize compositions for select pharmaceutical indications.

IceCure Medical Reports Financial Results for the First Half of 2021 and Recent Operating Highlights

Retrieved on: 
Thursday, September 23, 2021
Annals of Surgical Oncology, Clinical trial, Neoplasm, Breast, ICE3, Form, Partnership, OTC, Risk, National Breast Cancer Foundation, Surgical oncology, Private Securities Litigation Reform Act, NASDAQ, FDA, Cancer, Patient, Freezing, Nasdaq, MD, SEC, Kidney, FACS, Interim analysis, Education, Company, Recurrence, TASE, CE, R, Incidence, Time, Breast cancer, Society, Lithium, Medical imaging, Airline, Animal, Security (finance)

o Asian distribution partnership with Terumo Corporation (Tokyo: 4543, TRUMY:OTC US) expanded to include Thailand, in addition to Japan and Singapore.

Key Points: 
  • o Asian distribution partnership with Terumo Corporation (Tokyo: 4543, TRUMY:OTC US) expanded to include Thailand, in addition to Japan and Singapore.
  • The Company's ordinary shares commenced trading on the Nasdaq Capital Market on August 26, 2021.
  • "I am excited by our team's growing list of accomplishments throughout the business thus far in 2021.
  • Total operating expenses for the six months ended June 30, 2021 were approximately $4.9 million.

IceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer

Retrieved on: 
Monday, September 13, 2021
Form, Pain, Education, Continuity, FDA, Conference, TASE, Patient, Company, Interim analysis, Private Securities Litigation Reform Act, Society, CE, Excision, Surgical oncology, Kidney, Neoplasm, Safety, ICE3, NASDAQ, Trial of the century, Breast, MD, Recurrence, Disruptive innovation, Annals of Surgical Oncology, FACS, Freezing, Risk, SEC, Medical imaging

"Having a peer reviewed publication of the ICE3 Clinical Study [1]interim results in a well-respected medical journal represents a major milestone for IceCure in solidifying the efficacy and adaptation of its minimally invasive solution by the broader medical community for the treatment of certain breast cancers," stated IceCure CEO, Eyal Shamir.

Key Points: 
  • "Having a peer reviewed publication of the ICE3 Clinical Study [1]interim results in a well-respected medical journal represents a major milestone for IceCure in solidifying the efficacy and adaptation of its minimally invasive solution by the broader medical community for the treatment of certain breast cancers," stated IceCure CEO, Eyal Shamir.
  • The journal article concludes that "breast cryoablation presents a promising alternative to surgery while offering the benefits of a minimally-invasive procedure with minimal risks.
  • "[2] Study author Dr. Fine stated that "the 3-year ICE3 trial results highlighting the efficacy and safety of the procedure in this patient group are extremely promising for breast cryoablation.
  • The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

The American Journal of Managed Care® Announces Latest Institute for Value-Based Medicine® VB-Onc™ Meeting

Retrieved on: 
Thursday, March 14, 2019
Health, Hospitals, Oncology, Research, Science, Managed care, Academic journals, Periodicals, Publications, American Cancer Society, Cancer, The American Journal of Managed Care, JAMA Oncology, Annals of Surgical Oncology

The American Journal of Managed Care (AJMC), the leading peer-reviewed journal dedicated to issues in managed care, with its Institute for Value-Based Medicine will host a regional VB-Onc meeting that will examine how to deliver the best cancer care via the latest pay-for-performance models.

Key Points: 
  • The American Journal of Managed Care (AJMC), the leading peer-reviewed journal dedicated to issues in managed care, with its Institute for Value-Based Medicine will host a regional VB-Onc meeting that will examine how to deliver the best cancer care via the latest pay-for-performance models.
  • It will be moderated by Shalom Kalnicki, M.D., FASTRO, FACRO, professor and chairman, Radiation Oncology, Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine.
  • The American Journal of Managed Care (AJMC) is a peer-reviewed, Medline-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision-makers as they work to promote the efficient delivery of high-quality care.
  • Other titles in the AJMC family include The American Journal of Accountable Care and two evidence-based series, Evidence-Based Oncology and Evidence-Based Diabetes Management.